Global Meningococcal Disease Treatment Market, By Therapy Type (Antibiotics (Penicillin, Ampicillin, Chloramphenicol, and Ceftriaxone) and (Vaccines (Bivalent, Trivalent, and Tetravalent)), By Route of Administration (Injectable and Oral), By Distribution channel (Hospital Pharmacy, Retail Pharmacy, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 3,754.1 million in 2021 and is expected to exhibit a CAGR of 12.6% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
The increasing approval of product for the treatment of meningococcal disease is expected to drive the market growth during the forecast period. For instance, in April 2020, The U.S. Food and Drug Administration (FDA) granted biologics license application for Sanofi’s MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in 2 years and older individuals.
In 2014, Pfizer Inc., a pharmaceutical company has launched Trumenba Vaccine for Meningitis B in the U.S. for 10 to 25 years old individuals, infected with meningitis caused by Neisseria meningitidis serogroup B.
Global Meningococcal Disease Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
Due to the worldwide lockdown, all immunization program has been stopped and program schedule are changed in various countries as per the Covid-19 guidelines.
Research and development for activated vaccine and drug technology has been limited, as researchers need to stay at home during the lockdown.
Furthermore, in April 2020, University of Oxford U.K. has conducted a Covid-19 vaccine trial using Meningococcal vaccine placebo effect
Browse 35 Market Data Tables and 36 Figures spread through 151 Pages and in-depth TOC on “Meningococcal Disease Treatment Market”- Global Forecast to 2028, By Therapy Type (Antibiotics (Penicillin, Ampicillin, Chloramphenicol, and Ceftriaxone) and (Vaccines (Bivalent, Trivalent, and Tetravalent)), By Route of Administration (Injectable and Oral), By Distribution channel (Hospital Pharmacy, Retail Pharmacy, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Meningococcal Disease Treatment Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/meningococcal-disease-treatment-market-4913
Key Takeaways of the Global Meningococcal Disease Treatment Market:
- The global meningococcal disease treatment market is expected to exhibit a CAGR of 12.6% over the forecast period, owing to increasing incidences of meningococcal disease, which is expected to drive the market growth during the forecast period. According to the World health Organization (WHO) article published in 2018, meningococcal meningitis is observed at worldwide level but the highest burden of this disease is in the meningitis belt of sub-Saharan Africa, around 30,000 cases are still reported each year from sub-Saharan Africa area.
- Among therapy type, vaccine segment is accounted for the largest market share in 2020, owing to increasing R&D. For instance, in July 2020, Pfizer Inc., announced the initiation of phase 3 clinical trials of NCT04440163 of the pentavalent meningococcal vaccine candidate.
- Key players operating in the global meningococcal disease treatment market include GlaxoSmithKline Plc., Novartis AG, Sanofi Pasteur Inc., Wockhardt Ltd., Kent Pharmaceuticals, Stravencon Limited., F. Hoffmann-La Roche Ltd., Athlone Laboratories, and Pfizer Inc.
